Medical Oncology

, 31:55 | Cite as

Luminal breast cancer classification according to proliferative indices: clinicopathological characteristics and short-term survival analysis

  • Yan Sun
  • Gang Nie
  • Zhimin Wei
  • Zhidong Lv
  • Xiaoyi Liu
  • Haibo WangEmail author
Original Paper


The classification of luminal breast cancer has been a popular topic regarding its heterogeneity with distinct biological features and clinical outcomes. This study aimed to assess the power of proliferative indices (Ki67 and histological grade) to determine various clinicopathological characteristics and survival in luminal disease. A total of 541 patients with stage I–III luminal breast cancer were enrolled. Subtypes were determined using proliferative indices and were compared with clinicopathological variables and short-term survival. The significance of various treatments was evaluated in a subgroup of pN0 (lymph node negative) patients. Histological grade, independent of other variables, was a better predictor in the ER/PR+, human epidermal growth factor receptor 2 (Her-2) subgroup (p = 0.011) and the pN0 subgroup (p = 0.044) compared with Ki67, which only showed significance in the ER/PR+, Her-2 subgroup (p = 0.008). Neither grade nor Ki67 was associated with outcomes in the luminal Her-2 class. In pN0 patients, various treatments did not show significance in short-term survival. Histological grade outperformed Ki67 as a determinant for the stratification of luminal class regarding short-term survival. Chemotherapy most likely did not provide additional benefit to pN0 patients with luminal breast cancer compared with endocrine therapy.


Luminal breast cancer Classification Cell proliferation Ki67 Histological grade Short-term survival 



This study was supported by National Natural Science Foundation of China (No. 81302290).

Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol. 2005;205(2):248–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98(19):10869–74.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790–800.PubMedCrossRefGoogle Scholar
  5. 5.
    Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2010;220(2):263–80.PubMedGoogle Scholar
  6. 6.
    Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6(12):718–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319–29.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Ctsu RI. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  9. 9.
    Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12(12):1101–8.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158–65.PubMedCrossRefGoogle Scholar
  11. 11.
    Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Yanagawa M, Ikemot K, Kawauchi S, et al. Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC Res Notes. 2012;5(1):376.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Geyer FC, Rodrigues DN, Weigelt B, et al. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol. 2012;19(1):39–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Lips EH, Mulder L, de Ronde JJ, et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013;140(1):63–71.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Bhargava R, Striebel J, Beriwal S, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2(5):444.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Balleine RL, Wilcken NR. High-risk estrogen-receptor-positive breast cancer. Mol Diagn Therapy. 2012;16(4):235–40.CrossRefGoogle Scholar
  17. 17.
    Van Diest PJ, Van Der Wall E, Baak JPA. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;57(7):675–81.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Aleskandarany MA, Green AR, Benhasouna AA, et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res. 2012;14(1):R3.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Daidone MG, Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. JNCI Monogr. 2001;2001(30):27–35.CrossRefGoogle Scholar
  20. 20.
    Colozza M, Azambuja E, Cardoso F, et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol. 2005;16(11):1723–39.PubMedCrossRefGoogle Scholar
  21. 21.
    Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.PubMedCrossRefGoogle Scholar
  22. 22.
    Ivshina AV, George J, Senko O, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006;66(21):10292–301.PubMedCrossRefGoogle Scholar
  23. 23.
    de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504–13.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174–83.PubMedCrossRefGoogle Scholar
  25. 25.
    Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207.PubMedCentralPubMedGoogle Scholar
  26. 26.
    NHSBSP R. Pathological Reporting of Breast Disease: A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programmes Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of the Royal College of Pathologists’ Minimum Dataset for Breast Cancer Histopathology. Sheffield: NHSBSP, 2005.Google Scholar
  27. 27.
    Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Trihia H, Murray S, Price K, et al. International Breast Cancer Study Group: Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors–a surrogate marker. Cancer. 2003;97(5):1321–31.PubMedCrossRefGoogle Scholar
  29. 29.
    Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21(17):3357–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Leong SPL, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34(10):2308–24.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Spitale A, Mazzola P, Soldini D, et al. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2009;20(4):628–35.PubMedCrossRefGoogle Scholar
  32. 32.
    Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomark Prev. 2007;16(3):439–43.CrossRefGoogle Scholar
  33. 33.
    Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, J Am Med Assoc. 2006;295(21):2492–502.CrossRefGoogle Scholar
  34. 34.
    Vallejos CS, Gómez HL, Cruz WR, et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer. 2010;10(4):294–300.PubMedCrossRefGoogle Scholar
  35. 35.
    von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.CrossRefGoogle Scholar
  36. 36.
    Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133–44.PubMedCrossRefGoogle Scholar
  37. 37.
    Clahsen PC, Van de Velde CJH, Duval C, et al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol EJSO. 1999;25(4):356–63.CrossRefGoogle Scholar
  38. 38.
    Gong P, Wang Y, Liu G, et al. New insight into Ki67 expression at the invasive front in breast cancer. PLoS ONE. 2013;8(1):e54912.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Yan Sun
    • 1
  • Gang Nie
    • 1
  • Zhimin Wei
    • 2
  • Zhidong Lv
    • 1
  • Xiaoyi Liu
    • 1
  • Haibo Wang
    • 1
    Email author
  1. 1.Breast CenterQingdao University Affiliated HospitalQingdaoChina
  2. 2.Department of PathologyQingdao University Affiliated HospitalQingdaoChina

Personalised recommendations